Congratulations to Giant Biogene on its Successful Listing on the Main Board of the Hong Kong Stock Exchange | Gaorong Ventures News
"The first publicly traded collagen stock."
On November 4 Beijing time, Giant Biogene (stock code: 02367.HK), a leader in China's professional skin care products industry based on bioactive ingredients, listed on the main board of the Hong Kong Stock Exchange, becoming the "first collagen stock." Previously, in October 2021, Giant Biogene completed its only funding round since inception, with Gaorong Ventures participating as an investor.
Giant Biogene is a pioneer and leader in China's recombinant collagen industry. The core of its R&D team, Dr. Daidi Fan, is one of the leading figures in the collagen industry and even in China's biomedical materials field. After years of accumulation, Giant Biogene has established a synthetic biology technology platform that integrates interdisciplinary scientific research spanning biotechnology, biochemistry, and bioengineering, combined with years of industry expertise. Giant Biogene has successively developed 33 different types of recombinant collagen and successfully mass-produced them, in addition to independently developing and producing rare ginsenosides.
As of the time of listing, Giant Biogene's professional skin care products and health food portfolio comprised 106 SKUs across eight major brands, including its two flagship brands, Comfy and Collgene. Collgene and Comfy were respectively the third and fourth best-selling brands in China's professional skin care products industry in 2021 (by retail sales value).
In 2021, China's efficacy skin care products market reached 30.8 billion yuan. Giant Biogene was the second-largest professional skin care products company in China in 2021, and had been China's largest collagen-based professional skin care products company for three consecutive years since 2019.
While focusing on R&D capabilities and product strength, Giant Biogene maintained high-quality performance growth. Data shows that from 2019 to 2021, the company's revenue was 957 million yuan, 1.19 billion yuan, and 1.552 billion yuan respectively, representing a compound annual growth rate of approximately 27.39%; for the five months ended May 31, 2022, revenue and net profit reached 723 million yuan and 314 million yuan respectively, demonstrating strong profitability.
Technology and innovation are the fulcrum of Giant Biogene, and the lever that pries open exponential growth for the enterprise. Rui Han, partner at Gaorong Ventures, stated, "Giant Biogene fully deserves to be called a company that spent ten years sharpening one sword — its investment in product R&D and its innovative capabilities are astounding. Going forward, I believe that under the leadership of Professor Fan's scientific research capabilities and President Yan's entrepreneurial spirit, Giant will continue to create unique value."
